© Globe Newswire
17.12.2025
MBRX
LISTED
NASDAQ
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors
News Preview
Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
GPCR
LISTED
NASDAQ
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
News Preview
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
LEGN
LISTED
NASDAQ
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesda...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
17.12.2025
ALHC
LISTED
NASDAQ
Alignment Healthcare to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Alignment Healthcare, Inc. (NASDAQ: ALHC) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 14, at 10:30 a.m. PST....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
17.12.2025
CERO
LISTED
NASDAQ
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
News Preview
Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
VYNE
LISTED
NASDAQ
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
News Preview
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger agreement pursuant to which the companies will combine in an all-stock transaction (the “Merger”). Upon completion of the Merger, the combined company exp...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
SABS
LISTED
NASDAQ
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
News Preview
MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced positive, confirmatory data from a Phase 1 trial of SAB-142 in a single- and multiple-ascending...
Themefolio
Profiler
Peergroup
© Newsfile
17.12.2025
PMED
LISTED
CSE
Predictmedix AI Inc - 2025 Year End Corporate Update
News Preview
A Defining Year Positioning Predictmedix AI at the Convergence of Quantum, AI, and HealthcareToronto, Ontario--(Newsfile Corp. - December 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company") concludes 2025 having delivered a year of disciplined execution across technology development, global i...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
SVA
LISTED
NASDAQ
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
News Preview
Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Mr. Andrew Y. Yan and Mr. Yin Weidong (collectively, the Boar...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
MRK
LISTED
NYSE
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery
News Preview
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. The trial showed KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedot...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
CYTK
LISTED
NASDAQ
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
News Preview
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
HBIO
LISTED
NASDAQ
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
News Preview
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
17.12.2025
ACRV
LISTED
NASDAQ
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
News Preview
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpr...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
CMPX
LISTED
NASDAQ
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
News Preview
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
DYAI
LISTED
NASDAQ
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutrition, and Bioindustrial Markets
News Preview
Dyadic and Fermbox Bio Expand Strategic Collaboration to Accelerate Commercialization of Animal-Free Proteins and Enzymes Across Life Science, Food & Nutri...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
SGMT
LISTED
NASDAQ
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
News Preview
SAN MATEO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways for metabolic and fibrotic diseases, today announced entry into a license agreement with Assia Chemical Industries L...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
EYPT
LISTED
NASDAQ
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will present at the 44th Annual...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TNGX
LISTED
NASDAQ
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
News Preview
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 9:45am PST/12:45pm EST....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
CSTL
LISTED
NASDAQ
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
News Preview
New data show DecisionDx-UM combined with PRAME provides superior prediction of metastasis and survival in uveal melanoma compared to NGS....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TRDA
LISTED
NASDAQ
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Entrada Therapeutics announces an upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
NVCT
LISTED
NASDAQ
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
News Preview
The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung cancer (NSCLC) whose cancers initially responded to treatment with osimertinib but subsequently acquired resistance to treatment The study is designed...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
LFCR
LISTED
NASDAQ
Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer
News Preview
Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product...
Themefolio
Profiler
Peergroup
© Newsfile
17.12.2025
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness Signs A 10 Unit Development Agreement for the State of Colorado, USA
News Preview
Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce that its acai and smoothie bowl QSR brand, Heal Wellness ("Heal"), has entered into a 10-unit franchise development agreement...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
PSNL
LISTED
NASDAQ
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR). The paper, titled "Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunothe...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
VERU
LISTED
NASDAQ
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
News Preview
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an acceptable approvable primary endpoint with key secondary endpoints on physical function and body composition improvements --...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
TRAW
LISTED
NASDAQ
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
News Preview
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
MDCE
LISTED
OTC
Medical Care Technologies, Inc. (OTC Pink:MDCE) Announces Completion of AI-Based Consumer App, Now in iOS App Store Review
News Preview
MESA, ARIZONA / ACCESS Newswire / December 17, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is pleased to announce that its first AI-based consumer app in the food and nutrition space has completed testing and is now under review in the iOS App Store. The app will launch in 127 countries and 30 languages, with a Google Play Store review p...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
OPRX
LISTED
NASDAQ
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
News Preview
Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37% Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37%...
Themefolio
Profiler
Peergroup
© EQS Newswire
17.12.2025
HPHA
LISTED
XETR
Letter from the CEO
News Preview
Letter from the CEODear shareholders, partners, and friends of Heidelberg Pharma,
The past few months have been turbulent and difficult for Heidelberg Pharma. We have been confronted with events and changes that required swift and decisive action. Today, I am writing to you to explain where we stand - and, above all, why I am deeply convinced that......
Themefolio
Profiler
Peergroup
© EQS Newswire
17.12.2025
HPHA
LISTED
XETR
Brief des Vorstandsvorsitzenden
News Preview
Brief des Vorstandsvorsitzenden
Sehr geehrte Aktionäre, Partner und Freunde der Heidelberg Pharma,
die vergangenen Monate waren für Heidelberg Pharma unruhig und schwierig. Wir sahen uns mit Ereignissen und Veränderungen konfrontiert, die schnelles und konsequentes Handeln erforderten. Heute wende ich mich an Sie, um einzuordnen, wo wir stehen – u......
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
RKV
LISTED
TSX
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
News Preview
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that senior members of the Company’s executive leadership will be in San Francisco, C...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
UDOC
LISTED
CSE
UniDoc Completes H3 Health Cube Installation in Italy
News Preview
AI assisted Health Cube open to patients in Guardia Perticara (Basilicata), Italy VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company") is pleased to announce that it has completed installation of its H3 Health Cube in Italy. Sold through UniDoc's i...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
WGRX
LISTED
NASDAQ
Wellgistics Health Reminds Shareholders of December 19, 2025 Record Date for Dream Bowl 2026 Meme Coin Tokens
News Preview
TAMPA, FL / ACCESS Newswire / December 17, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, to...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
BAVA
LISTED
CPH
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
News Preview
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
ALVO
LISTED
ICE
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
News Preview
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDIT...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
CNSP
LISTED
NASDAQ
CNS Pharmaceuticals Announces CEO Transition
News Preview
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brai...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
MRNA
LISTED
NASDAQ
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
ALSAF
LISTED
EURONEXT
SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS
News Preview
SAFE SIGNS A STRATEGIC DISTRIBUTION AGREEMENT IN SPAIN WITH VORTROM BIOLOGICS...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
GALD
LISTED
XWSX
New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the ph...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
SAN
LISTED
EURONEXT
Press release: Availability of the Q4 2025 Aide memoire
News Preview
Availability of the Q4 2025 Aide memoire...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
NYXH
LISTED
NASDAQ
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands
News Preview
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the NetherlandsFirst Genio implants successfully performed at OLVG West and Zuyderland hospitals...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
SAN
LISTED
EURONEXT
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
News Preview
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
GSK
LISTED
NYSE
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
News Preview
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
The FDA approval of Exdensur is based on data from the SWIFT-1 and S...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
17.12.2025
XPHY
LISTED
CSE
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
News Preview
VANCOUVER, BC / ACCESS Newswire / December 17, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce significant progress in its mission to address one of the most overlooked barriers in medicine: sw...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
GEHC
LISTED
NASDAQ
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners
News Preview
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will su...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2025
IMNM
LISTED
NASDAQ
Immunome Announces Pricing of Public Offering of Common Stock
News Preview
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 18,625,000 shares of its common stock at a price to the public of $21.50 per share. All of the shares are to be sold by Immunome.
Th...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
VREO
LISTED
CSE
Vireo Growth Inc. Enters into Definitive Agreement to Acquire Certain Assets of PharmaCann Inc.
News Preview
Acquired assets further optimize Vireo’s operating footprint in Colorado with addition of 17 dispensaries...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
ANNX
LISTED
NASDAQ
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.12.2025
13
LISTED
HKSE
HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
News Preview
— First-in-human trial of candidate from the next-generation ATTC platform —...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
HUM
LISTED
NYSE
AM Best Affirms Credit Ratings of Humana Inc. and Its Subsidiaries
News Preview
AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) for the health and dental insurance subsidiaries of Humana Inc. (Humana) (headquartered in Louisville, KY) [NYSE: HUM]. These subsidiaries collectively are referred to as Humana Health Group. In addit...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
INBX
LISTED
NASDAQ
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
News Preview
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for pa...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
SOLV
LISTED
NYSE
Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
News Preview
ST. PAUL, Minn., Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare. This certification validates Solventum's MedSurg segment's ability to deliver cr...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
ILMN
LISTED
NASDAQ
Illumina To Webcast Upcoming Investor Conference
News Preview
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:
Upcoming Investor Conference44th Annual J.P. Morgan Healthcare Conference on January 13, 2026The presentation is scheduled for 7:30 a.m. PT (10:30 a.m. ET), with a Q&A...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
VIR
LISTED
NASDAQ
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Austr...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
KRMD
LISTED
NASDAQ
KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer
News Preview
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective Decembe...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
GDRX
LISTED
NASDAQ
GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for medication savings in the U.S., today announced that executives from the Company will participate in a fireside chat at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 1:30 p.m. Pacific Time (4:30 p.m. E...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2025
NBIX
LISTED
NASDAQ
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
News Preview
Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic ModalitiesReviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027Announc...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2025
STOK
LISTED
NASDAQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effe...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2025
SLDB
LISTED
XNMS
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
News Preview
CHARLESTOWN, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS) officially added Duchenne muscular dystrophy (Duchen...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2025
MAIA
LISTED
XASE
MAIA Biotechnology Announces $1.51 Million Private Placement
News Preview
CHICAGO, IL, Dec. 16, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,233,488 shares of common st...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
